Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SNDX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSyndax raises $243M from convertible debt offering, up to 13.6M shares at risk of dilution
Filed June 10, 2026 · Period ending June 10, 2026 · ~1 min read
Key Changes
-
high
Syndax issued $250M of 2.25% convertible senior notes due 2031, netting $243M after fees. Funds will support R&D, commercialization, and general corporate needs.
Item 1.01 verify on EDGAR → -
high
Up to 13.6M new shares could be issued if noteholders convert their debt to equity at the initial rate of 54.5 shares per $1,000 of principal, representing potential dilution to current shareholders.
Item 3.02 verify on EDGAR → -
medium
Notes were sold in a private placement to qualified investors using SEC registration exemptions, with U.S. Bank Trust serving as trustee under the indenture.
Item 9.01 verify on EDGAR →
Summary
Syndax Pharmaceuticals closed a $250 million convertible debt offering on June 10, 2026, bringing in $243 million after fees. The 2.25% notes mature in 2031 and can convert into common stock at a rate that could create up to 13.6 million new shares—meaningful dilution for existing holders if conversion occurs. The company plans to use proceeds for research and development, commercialization activities, and general corporate purposes including business development.
For retail investors, the key question is whether Syndax's pipeline and commercial execution can justify the dilution risk. Convertible debt is common in biotech as it provides cheaper financing than equity while delaying dilution, but conversion becomes likely if the stock price rises significantly. Watch for updates on clinical trial progress and product launches that would drive the need for this capital and potentially trigger conversion.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The Company’s net proceeds from the Private Placement were approximately $243.0 million, after deducting the placement agent’s fees and Private Placement expenses payable by the Company. The Company expects to use the net proceeds from the Private Placement for general corporate purposes, including working capital, research and development expenditures, commercialization activity expenditures and business development expenditures.
After fees and expenses, Syndax received approximately $243 million in net proceeds. The company plans to deploy this capital across general corporate needs including working capital, R&D spending, commercialization activities, and business development initiatives.
Event · Item 2.03 — Creation of a Direct Financial Obligation
Syndax disclosed creation of a direct financial obligation, with details incorporated by reference from Item 1.01.
Added in current filing · verify on EDGAR →
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The company disclosed the creation of a direct financial obligation or off-balance sheet arrangement. The specific terms and details are referenced in Item 1.01 of the filing, which is not included in the provided text. This typically indicates new debt, credit facility, or similar financing arrangement.
Event · Item 3.02 — Unregistered Sales of Equity Securities
Syndax sold convertible notes in a private placement, potentially issuing up to 13.6M shares upon conversion.
Added in current filing · verify on EDGAR →
The Company offered and sold the Notes to certain investors in reliance on the exemption from registration provided by Section 4(a) (2) of the Securities Act of 1933, as amended (the “Securities Act”). The Company relied on this exemption from registration based in part on representations made by each investor in the subscription agreements, dated June 3, 2026, between the Company and each investor identified therein.
Syndax completed a private placement of convertible notes to certain investors on June 3, 2026, using an exemption from SEC registration requirements under Section 4(a)(2) of the Securities Act. The notes were sold through subscription agreements with qualified investors.
Added in current filing · verify on EDGAR →
To the extent that any shares of Common Stock are issued upon conversion of the Notes, they will be issued in transactions anticipated to be exempt from registration under the Securities Act by virtue of Section 3(a) (9) thereof as involving an exchange by the Company exclusively with its noteholders because no commission or other remuneration is expected to be paid in connection with conversion of the Notes and any resulting issuance of shares of Common Stock.
Any shares issued upon note conversion will use another registration exemption (Section 3(a)(9)) because the conversion involves only an exchange between the company and noteholders with no commissions or fees paid. This allows the company to issue shares without a separate registration process.
Event · Item 9.01 — Financial Statements and Exhibits
Syndax issued 2.25% convertible senior notes due 2031, filing the indenture and note form with U.S. Bank Trust as trustee.
Added in current filing · verify on EDGAR →
Indenture, dated as of June 10, 2026, by and between Syndax Pharmaceuticals, Inc. and U.S. Bank Trust Company, National Association, as Trustee
Syndax entered into an indenture on June 10, 2026 with U.S. Bank Trust Company as trustee to govern newly issued convertible senior notes. This establishes the legal framework and trustee relationship for the debt offering.
Added in current filing · verify on EDGAR →
Form of Global Note, representing Syndax Pharmaceuticals, Inc.’s 2.25% Convertible Senior Notes due 2031
The company issued convertible senior notes with a 2.25% coupon rate maturing in 2031. These notes can be converted into Syndax common stock under terms specified in the indenture, providing investors with equity upside potential while adding debt to the balance sheet.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify